277 related articles for article (PubMed ID: 23291989)
1. Distinct survival benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in revascularized coronary artery disease patients according to history of myocardial infarction.
Nishino T; Furukawa Y; Kaji S; Ehara N; Shiomi H; Kim K; Kitai T; Kinoshita M; Morimoto T; Sakata R; Kimura T;
Circ J; 2013; 77(5):1242-52. PubMed ID: 23291989
[TBL] [Abstract][Full Text] [Related]
2. Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents.
Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Cardiovasc Drugs Ther; 2019 Feb; 33(1):55-67. PubMed ID: 30632033
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
[TBL] [Abstract][Full Text] [Related]
4. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention.
Byun JK; Choi BG; Rha SW; Choi SY; Jeong MH;
Atherosclerosis; 2018 Oct; 277():130-135. PubMed ID: 30212681
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.
Sorbets E; Labreuche J; Simon T; Delorme L; Danchin N; Amarenco P; Goto S; Meune C; Eagle KA; Bhatt DL; Steg PG
Eur Heart J; 2014 Jul; 35(26):1760-8. PubMed ID: 24616336
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker.
Hara M; Sakata Y; Nakatani D; Suna S; Usami M; Matsumoto S; Sugitani T; Nishino M; Sato H; Kitamura T; Nanto S; Hamasaki T; Hori M; Komuro I;
Am J Cardiol; 2014 Jul; 114(1):1-8. PubMed ID: 24819900
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-Converting Enzyme Inhibitor-based Versus Angiotensin Receptor Blocker-based Optimal Medical Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study.
Park S; Kim YG; Ann SH; Park HW; Suh J; Roh JH; Cho YR; Han S; Park GM
J Cardiovasc Pharmacol; 2021 Jan; 77(1):61-68. PubMed ID: 33165139
[TBL] [Abstract][Full Text] [Related]
8. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction.
Raposeiras-Roubín S; Abu-Assi E; Cespón-Fernández M; Ibáñez B; García-Ruiz JM; D'Ascenzo F; Simao Henriques JP; Saucedo J; Caneiro-Queija B; Cobas-Paz R; Muñoz-Pousa I; Wilton SB; González Juanatey JR; Kikkert WJ; Núñez-Gil I; Ariza-Solé A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Gaita F; Huczek Z; Nie SP; Yan Y; Fujii T; Correia L; Kawashiri MA; Kedev S; Southern D; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Giordana F; Kowara M; Filipiak K; Wang X; Fan JY; Ikari Y; Nakahayshi T; Sakata K; Yamagishi M; Kalpak O; Íñiguez-Romo A
Rev Esp Cardiol (Engl Ed); 2020 Feb; 73(2):114-122. PubMed ID: 31105064
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction.
Lee JH; Bae MH; Yang DH; Park HS; Cho Y; Lee WK; Jeong MH; Kim YJ; Cho MC; Kim CJ; Chae SC;
Korean J Intern Med; 2016 Mar; 31(2):267-76. PubMed ID: 26701233
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Lim S; Choo EH; Choi IJ; Ihm SH; Kim HY; Ahn Y; Chang K; Jeong MH; Seung KB
J Korean Med Sci; 2019 Nov; 34(45):e289. PubMed ID: 31760711
[TBL] [Abstract][Full Text] [Related]
11. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
[TBL] [Abstract][Full Text] [Related]
12. A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents.
Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Atherosclerosis; 2019 Oct; 289():109-117. PubMed ID: 31491742
[TBL] [Abstract][Full Text] [Related]
13. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
[TBL] [Abstract][Full Text] [Related]
15. Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention.
Lin MJ; Chen CY; Lin HD; Wu HP
BMC Cardiovasc Disord; 2017 Jan; 17(1):12. PubMed ID: 28056847
[TBL] [Abstract][Full Text] [Related]
16. Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention.
Ann SH; Strauss MH; Park GM; Han S; Yang Y; Kim YG; Won KB; Kim SJ; Lee SG; Cho YR; Kim DW; Park MW; Her SH; Lee SW
Int J Cardiol; 2020 May; 306():35-41. PubMed ID: 31727411
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
Steely AM; Callas PW; Bertges DJ;
J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
[TBL] [Abstract][Full Text] [Related]
18. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
Puri R; Nissen SE; Menon V; Shao M; Hsu A; Bakris GL; Kastelein JJ; Williams B; Armbrecht J; Brunel P; Kataoka Y; Nicholls SJ
Atherosclerosis; 2015 Dec; 243(2):553-9. PubMed ID: 26523993
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin inhibition after myocardial infarction: does drug class matter?
Winkelmayer WC; Fischer MA; Schneeweiss S; Levin R; Avorn J
J Gen Intern Med; 2006 Dec; 21(12):1242-7. PubMed ID: 17105523
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
